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Quantitative neuropathological assessment to
investigate cerebral multi-morbidity
Johannes Attems1*, Janna H Neltner2 and Peter T Nelson2
Abstract
The aging brain is characterized by the simultaneous presence of multiple pathologies, and the prevalence of cerebral
multi-morbidity increases with age. To understand the impact of each subtype of pathology and the combined effects
of cerebral multi-morbidity on clinical signs and symptoms, large clinico-pathological correlative studies have been
performed. However, such studies are often based on semi-quantitative assessment of neuropathological hallmark
lesions. Here, we discuss some of the new methods for high-throughput quantitative neuropathological assessment.
These methods combine increased quantitative rigor with the added technical capacity of computers and networked
analyses. There are abundant new opportunities - with specific techniques that include slide scanners, automated
microscopes, and tissue microarrays - and also potential pitfalls. We conclude that quantitative and digital
neuropathologic approaches will be key resources to further elucidate cerebral multi-morbidity in the aged
brain and also hold the potential for changing routine neuropathologic diagnoses.
Cerebral multi-morbidity
It is becoming increasingly clear that, as a rule, the aging
brain is characterized by the simultaneous presence of
multiple neuropathological lesions rather than the
hallmark lesion(s) of a single age-associated neurode-
generative disease [1]. Moreover, the prevalence of this
cerebral multi-morbidity increases with age, and post-
mortem studies indicate that, in brains of demented
individuals over 80 years of age, the presence of only
one, single disease is a rare finding [2-7]. More details
regarding the prevalence of mixed pathologies can be
found in the article by Rahimi and Kovacs in the
present review series of Alzheimer’s Research & Therapy
[8]. Alzheimer’s disease (AD) in particular often presents
with comorbid processes, including cerebrovascular dis-
ease, Lewy body (LB) pathology, argyrophilic grain disease,
transactivation response DNA binding protein 43 kDa
(TDP-43) pathology, and hippocampal sclerosis, and
about two-thirds of aged human brains contain substantial
non-AD pathology [9-11]. Indeed, in AD that is neuro-
pathologically characterized by amyloid-beta (Aβ) and
tau pathology (hyperphosphorylated tau), LB pathology
(α-synuclein) is present in up to 43% [1,12] (AD with
LBs restricted to the amygdala is considered a distinct
form of α-synucleinopathy [12]) and severe cerebrovascular
lesions are observed in up to 20% [2] of cases, respectively.
TDP-43 pathology often but not invariably restricted to the
amygdala and granule cell layer of the dentate gyrus and
entorhinal cortex is present in up to 57% [11,13-15], and
recently Josephs and colleagues [15] demonstrated that
TDP-43 is an important factor in the manifestation of
clinico-imaging features of AD. In LB disease that is
characterized by α-synuclein pathology, we found Aβ
pathology in 95% of cases, considerable tau pathology
(Braak stages V/VI) in 55%, and various degrees of
cerebrovascular pathology in 75% [16]. Both Aβ path-
ology (semi-quantitative scores [17]) and tau pathology
(Braak stages [18]) correlated with LB pathology, and
co-localization between hyperphosphorylated tau and
α-synuclein has been reported [12,17]. Pure vascular
dementia without additional lesions is rare (for example,
12.3% in [4]), and frequently additional AD pathology is
present. Whereas the common presence of neuropatho-
logic comorbidities has been described in many autopsy
series, the clinical diagnosis of multiple neurodegenerative
pathologies in one single patient remains challenging and
additional pathologies are often clinically unnoticed [19].
This may partially be due to a lack of clinico-pathological
correlative studies that identified subtle clinical signs and
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symptoms that could point toward additional concomitant
pathologies.
Quantitative neuropathological assessment
Clinico-pathological correlative studies are frequently based
on semi-quantitative data and ordinal-type parameters to
define the amount of pathology present in a given post-
mortem brain. These semi-quantitative data are usually
provided on standardized four-tiered ordinal scales: absent,
mild, moderate, and severe (for example, for tau [20] and
α-synuclein [21]). Although such semi-quantitative data are
very useful for providing the neuropathological diagnosis,
they often inaccurately reflect the actual amount of
pathology present and this has major implications when
data from large clinico-pathological correlative studies
are entered into databases, since cases that might actu-
ally differ quite considerably regarding the amount of
pathology fall into the same category. For example, we
found that the amount of tau pathology in cases semi-
quantitatively scored ‘severe’ differed significantly when the
actual area covered by immunopositivity was measured [1].
It is likely that new clinico-pathological phenotypes more
accurately reflecting cerebral multi-morbidity would be
identified by assessing the amount of pathology in a more
quantitative way.
Indeed, in quantitatively assessing entorhinal and
hippocampal tau pathology in a large cohort (n = 889)
of both clinically and neuropathologically diagnosed AD
cases, Murray and colleagues [22] identified typical AD
as well as hippocampal sparing and limbic predominant
subtypes of AD. When comparing their quantitative
neuropathological data with clinical findings, the authors
found that these subtypes of AD differed in clinical pres-
entation, age at onset, disease duration, and rate of cogni-
tive decline from typical AD [22]. In a subsequent study,
the authors found that magnetic resonance imaging (MRI)
could predict these subtypes during life since hippocampal
sparing AD showed the most severe cortical atrophy while
the most severe medial temporal atrophy was observed in
limbic predominant AD [23]. Of note, these AD subtypes
and their associations with cortical atrophy in MRI would
not have been identified if only semi-quantitative method-
ologies were employed, since all cases showed ‘severe’
entorhinal tau pathology. Only by the use of quantitative
measurements did the ‘severe’ group show differences
in the actual amount of pathology present. The authors
more recently demonstrated that limbic predominant
AD differed from neurofibrillary tangle (NFT) dominant
dementia as the latter showed significantly less tau
pathology in the mid-frontal cortex [24]. The authors
also suggested that, in hippocampal sparing AD, tau
pathology may begin in the neocortex, since they found a
fourfold increase in the amount of neocortical late-stage
tau (antibody Ab39 to a conformational epitope in NFTs
detecting late-stage tangles [25]) in hippocampal sparing
AD compared with typical AD [24]. The findings from
two large clinico-pathological correlative studies - the
Nun Study and the Adult Changes in Thought (ACT)
Study - indicated that 12% (Nun Study) and 8% (ACT
Study) of non-demented subjects showed severe AD path-
ology reflected by Braak stage V-VI. However, quantitative
assessment of NFT in both frontal and temporal cortices
revealed that these non-demented subjects showed less
NFT compared with demented subjects with Braak stage
V-VI [26] and demonstrated a considerable range of path-
ology within Braak stage VI [27]. It is important to note
that true ‘end-stage’ neurofibrillary pathology, measured
with quantitative methods, has never been associated with
an individual patient with ante-mortem intact cognition
[27]. The density of neuritic plaques and NFTs rose sig-
nificantly as a function of severity of dementia in subjects
who were 60 to 80 years old, but no such association was
found when subjects were over 90 years old [28], suggest-
ing that additional factors contribute to the development
of dementia in the oldest old.
The examples given above clearly indicate that quantita-
tive neuropathological assessment allows the identification
of clinico-pathological associations that are not detected
by using semi-quantitative assessment alone. Moreover,
given that quantitative assessment of tau pathology in AD
cases points toward new clinico-pathological phenotypes
[22], we assume that quantitative assessment of various
neuropathological lesions in large autopsy cohorts would
be beneficial to further elucidate possible mutual relation-
ships between pathologies as well as their combined
influence on the clinical picture. Hence, large clinico-
pathological correlative studies could identify subtle clinical
features that point toward underlying pathologies. However,
manual methods of quantitative assessment are time-
consuming since they involve either manual inspection
of histological slides with visual counting of pathological
lesions or importing individual images into an image
analysis system for further analysis. Hence, automated
methods for quantitative assessment might be helpful to
investigate large study cohorts and to perform quantifica-
tion in a routine setting.
Automated quantitative neuropathological
assessment
Of note, the aim of this section is not to provide a
detailed methodological description (which is outside
the purview of this review article) or a comprehensive
summary of all systems that might be currently used in
other centers. Rather, we aim to give an overview of two
methodologies for automated quantitative assessment that
are currently used in our own laboratories, and we refer to
our own published studies that successfully employed
these methods.
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Slide scanner and digital pathologic image analysis
Digital pathology offers a valuable resource for quantita-
tive pathology in neurodegenerative disease. In the recent
consensus recommendation article sponsored by the
National Institutes of Health and the Alzheimer’s
Association [29], it was noted that ‘both quantitative and
qualitative aspects of AD neuropathologic change have
significance, but current diagnostic methods are not
robustly quantitative and/or not systematically qualitative’.
This statement confirms that more quantitative diagnostic
methods are required in both the clinical and research set-
tings. Toward those goals, digital pathology offers multiple
benefits that surpass both semi-quantitative methods
and manual counts. Digital algorithms offer a superior
reproducibility and higher throughput performance that
could enable a far more standardized approach to the
assessment of AD neuropathologic changes (ADNCs).
If individual centers began to use a standard algorithm
for quantification, results could be used across institutions,
exponentially increasing the statistical power available to
all centers involved. Among the options for returning
quantitative changes in pathologies, the digital approach is
relatively efficient when it comes to manpower. With
these algorithms, more pathology can be counted faster
and more reproducibly than by manual inspection
alone. In addition, more parameters can be rigorously
examined, from staining intensity to plaque size and
more as described below. As our use of this technology
advances, it will open up a new understanding of the
pathologies in human brain aging. Here, we provide some
examples of results derived from the Aperio ScanScope
(Leica Biosystems, Nussloch, Germany), which is used
routinely at the University of Kentucky to document
pathologic changes, including both neurodegenerative
disease pathology and other subtypes of brain disease,
that affect older persons. Over 100 slides can be scanned
automatically in a batch. Although it does take additional
time to scan the slide and set up the analysis windows
(approximately 45 minutes to prepare and scan at 40×
via the semi-automated method and an additional
510 minutes to select the analysis windows per slide),
the bulk of the analysis work is done by the server
alone. These analyses can be set up during the day and
then allowed to run overnight without interruption
(120 slides per night). In addition, neuropathologic expert-
ise is not a requirement for this method, and we found
that workers at various phases of training could all come
up with very similar results in scoring ADNC quantifi-
cation [30]. As the analysis algorithms are held constant,
regardless of who sets up the windows, the data are
consistent. In future endeavors, this could be expanded to
involve algorithm sharing between institutions and thus
improve the inter-rater reliability between the different re-
search centers to help standardize the field of quantitative
ADNCs. In specific applications, digital pathology can
be used for both novel discoveries and routine clinical
duties. For example, although manually quantified ADNC
numbers suggested that Aβ plaque burden leveled off with
increasing neurofibrillary pathology [31,32], we failed to
identify that it actually decreases with increasing tau
burden by our manual methods alone. However, this
phenomenon could be well demonstrated with digital
methods [30]. Additionally, it has previously been shown
that apolipoprotein ε4 alleles correlate with increased Aβ
plaque pathology [33-36]; however, we could demonstrate
with digital methods that the plaque burden was partly
related to larger plaques, not just more plaques [30].
These data may enable other new insights into the patho-
logic changes seen in AD. In addition to the benefits for
research, these data may be appreciated by clinicians who
may desire more than a semi-quantitative idea about
neuropathologic burden. Figure 1 shows a panel of pho-
tomicrographs depicting pathologic lesions that can be
detected and quantified, along with a pathologic readout
showing the data that are obtained for each patient and
used for routine diagnostic practices at the University of
Kentucky. The potential benefits of quantitative digital
pathologic assessment extend beyond the description of
‘inclusion bodies’ that characterize many neurodegener-
ative diseases. This is important because many of the
comorbid pathologies in the aged human brain involve
additional subtypes of disease, including almost univer-
sal aging-related vascular, inflammatory, and metabolic
changes [37-40]. As such, there are many additional new
opportunities to study features of brain histomorphology
that have been hitherto constrained by the intrinsic
limitations of the human eye for detecting and quanti-
fying geometric characteristics. Morphology of blood
vessels - particularly, small blood vessels - provides an
important subject area that confounded prior method-
ologies. Aged brains contain many subtypes of small-
vessel changes, including cerebral amyloid angiopathy,
arteriolosclerosis, expanded Virchow-Robin spaces, small
hemorrhages with hemosiderinladen macrophages, and
micro-infarcts [4,41,42]. A novel approach using the
ScanScope digital pathologic algorithms was able to
make novel discoveries [43], assessing the morphologic
characteristics of capillaries (immunolabeled with an
antibody raised against CD34) and arterioles (immuno-
labeled with an antibody raised against alpha-smooth
muscle actin). This method was applied to demonstrate, in
quantitative fashion, that hippocampal sclerosis of aging in
humans [44] is associated with arteriolosclerosis in areas
outside of the hippocampus [43]. This analysis would be
difficult otherwise, given the lack of a rigorous universal
definition of arteriolosclerosis. Figure 2 is a panel to illus-
trate some of the parameters that can be gleaned by the
software when analyzing sections that are immunostained
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for small-blood vessel profiles. Additionally, the new tech-
nology was applied to query neuroinflammation in animal
models [45] by analyzing inflammatory cells in mice
brains. These experiments included assessment of both
quantitative neuroinflammatory changes (number of astro-
cytes or macrophages in a tissue) and qualitative changes
(macrophage activation was addressed by querying macro-
phages in different morphologic states). Finally, digital
Figure 1 Digital quantification of tau pathologies. (A) Analyses are performed on a paired helical filament-1 immunostained section. (B) After
the crafted Genie neurofibrillary tangle/neuritic plaque (NFT/NP) algorithm was used to isolate the NFTs, the NFT density (NFTs/mm2) is determined
by a modified nuclear algorithm, with NFT pseudo-colored yellow. (C) In a similar manner, the NP burden is calculated by first using the same crafted
Genie algorithm to isolate the NPs, here pseudocolored orange. (D) An overall tau burden is also calculated: red: positive immunohistochemical (IHC)
staining; blue: negative IHC staining. Scale bar, 25 μm. (E) A sample of the data that are provided in each pathology report from the University of
Kentucky for a quantitative description of Alzheimer’s disease (AD) pathology. ADNC, Alzheimer’s disease neuropathologic change; CA1, hippocampus
sector CA1; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; Inf, inferior; SMTG, superior and middle temporal gyri.
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pathologic methods enable the study of larger areas of the
brain and photomontages to depict multiple pathologic fea-
tures in those brain areas [46]. Despite the benefits of the
digital pathology methods, there are potential drawbacks.
The cost of digital pathology could be problematic for some
centers and hospitals: hundreds of thousands of dollars for
a machine that also requires costly service contracts for
future use (currently for the Aperio ScanScope used at the
University of Kentucky, the service contract costs over
$30,000 USD per year). Furthermore, for a longitudinal
study, there is always the question of whether that system
will remain well supported by the manufacturer and
whether future work will be directly comparable after
the inevitable changes in technology. Whole slide
analysis was the theoretical goal, but the massive
amount of analysis time this required made this an
impractical one. There are also specific areas of difficulty.
For example, a challenging pathology to quantitate is the
neuritic plaque. Owing to the heterogeneous nature of
these lesions, single plaques are challenging to count indi-
vidually. We note that the difficulty in this regard is also
reflected by a general lack of consensus on what exactly
defines these lesions (silver stain, thioflavine, or tau immu-
nohistochemistry can be used). Also, there are drawbacks
to the quantification of immunohistochemical phenomena
because those phenomena can be labile to various tech-
nical factors, including fixation time and inevitable
variabilities in chromagen development.
Figure 2 Digital quantification in a brain section using alpha-smooth muscle actin (α-SMA) immunohistochemistry which labels arterioles.
Actual immunohistochemical stain is brown (A) whereas the digital detection of those markers is pseudocolored green (B) after digital analyses were
run. This is the basis for further in silico analyses of the blood vessel morphology. Scale bars, 100 μm. (C) A sample of the data that are collected from
each analysis. Note that aspects of the blood vessel lumen, in addition to the lumen wall, are measured in a systematic way.
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Automated microscopes
Fully automated microscopes coupled to a personal com-
puter (PC) and software represent another possibility to
perform large-scale quantitative assessment. By conven-
tional image analysis, photomicrographs are individually
imported into the image analysis software, and subse-
quently adequate thresholds are set for measurement.
Automated microscopes, on the other hand, may be
entirely controlled by software allowing multiple images
to be taken automatically; after a specific area of interest
on the histological slide is set, multiple images covering
this area are taken automatically and then combined into
a single large image which is used for measurement (see
[47,48]). As images need not be imported individually, this
automated method is time-saving. Using this method-
ology, we could demonstrate that only the amount of
neuronal cell loss in the substantia nigra correlated with
reduced striatal 123I-FP-CIT SPECT (single-photon emis-
sion computed tomography) uptake but that the amount
of hyperphosphorylated tau, Aβ, and α-synuclein in
both striatum and substantia nigra had no influence on
striatal 123I-FP-CIT SPECT uptake [47]. These findings
were possible only by using a quantitative methodology
as semi-quantitative assessment shows ‘severe’ nigral
cell loss and ‘severe’ amounts of hyperphosphorylated
tau, Aβ, and α-synuclein pathology in most cases, making
it impossible to detect any differences with regard to the
amount of pathology in this study cohort. Recently, we
could also demonstrate in human brain tissue that the
amount of hyperphosphorylated tau pathology correlates
with that of pyroglytamylated Aβ but that no respective
correlation was observed between hyperphosphorylated
tau and non-pyroglutamylated Aβ [48]. These findings
suggest that pyroglytamylated Aβ plays a crucial role in
the pathogenesis of AD. Automated microscopes can also
be used to quantify pathology on tissue microarrays
(TMAs); of note, TMA methodology is often used in can-
cer research in which one slide contains samples of many
different cases. However, in the Newcastle Brain Tissue
Resource (Newcastle University, UK), these TMAs are
used to assess 40 different regions from any given case.
Samples for TMAs from prefrontal (BA9), frontal (BA8),
cingulate (BA32/24), motor (BA4), parietal (BA40/22),
occipital (BA17), temporal (BA21), and entorhinal (BA28/
27) cortices are taken from paraffin-embedded tissue blocks
(previously used for conventional neuropathological assess-
ment) by using a 3-mm tissue sampler (Tissue-Tek Quick-
Ray TMA System; Sakura, Torrance, CA, USA), and a
single, regular-sized (40 × 30 × 5 mm) paraffin block
containing all 40 samples is produced. Sections from
this TMA block are routinely stained with antibodies
against hyperphosphorylated tau, Aβ, and α-synuclein
but are available for other immunohistochemical stains
as well. To assess TMAs quantitatively, a so-called macro
(that is, executive chain of commands) is created by using
the image analysis software, NIS Elements (Nikon, Tokyo,
Japan); 40 coordinates which correspond to the location of
the TMA samples on the slide are set. The fully motorized
Nikon 90i microscope is controlled entirely by PC/soft-
ware, and with a 40× objective (400× magnification), the
first acquisition of 3 × 3 images is performed in the center
of the first TMA sample (top left). Image analysis is then
performed automatically on the combined image, which
represents an area of 1.7 mm2, using standardized thresh-
olds: red-green-blue thresholds that determine the pixels
that are included in the binary layer used for measurement
are standardized separately for each immunostain (that is,
hyperphosphorylated tau, Aβ, and α-synuclein). We set
the thresholds at a level that is reached by immunoposi-
tive pathological structures only (that is, NFTs, neuropil
threads, Aβ plaques/depositions, and LBs/neurites), but
unspecific background staining and structures that do not
show immunopositivity (for example, corpora amylacea)
do not reach the threshold and thus are not included into
the measurement.
The obtained data are automatically stored in a data-
base. The microscope stage then moves automatically to
allow image acquisition of the next TMA sample, and
the procedure is repeated until images of all 40 samples
are measured. Of note, before each image acquisition,
autofocus is performed. The assessment of one TMA
takes approximately 30 minutes and therefore is suited to
be used in a routine setting. Of note, only the database
containing the values of the areas covered by immunopo-
sitivity are kept on the PC/storage medium, whereas the
images that were used for measurement are deleted (the
original slides can be re-assessed if necessary). Hence, no
extensive storage capacity is needed to keep the data.
Using this methodology, we currently assessed over 100
post-mortem brains, including AD, LB disease, and con-
trols. One interesting finding was that the percentage area
covered by immunopositivity (hyperphosphorylated tau,
Aβ, and α-synuclein) differed considerably within semi-
quantitative categories, in particular in areas that were
semi-quantitatively scored ‘severe’, where, for example, the
percentage area for hyperphosphorylated tau immunopo-
sitivity ranged from 10% to over 30%. This further high-
lights the need for quantitative data in studies aiming to
identify subtle and novel clinico-pathological phenotypes
which may be characterized by the simultaneous presence
of multiple pathologies.
Conclusions
Some recent discoveries were made possible only by
using quantitative methodologies for the assessment of
neuropathological lesions. We described some of the new
methodologies that allow such a quantification at high
throughput, but more methodologies are currently being
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developed. These techniques will enable the identification
of new clinico-pathological phenotypes that reflect cere-
bral multi-morbidity of the aging brain. It is hoped that
future studies identify specific clinical signs or biomarkers
that more specifically point toward specific underlying
neuropathologies, with respect to both their quantity and
quality. Such studies are indeed warranted to allow an
accurate stratification of patients in clinical trials and to
further elucidate possible interactions between different
pathological processes in the aging brain.
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